INNOVENT BIO (01801) saw its shares rise more than 4% in afternoon trading. At the time of writing, the stock was up 3.73% to HKD 86.1, with a turnover of HKD 625 million. The movement follows an announcement from the company regarding the presentation of long-term follow-up data from key studies for its next-generation ROS1 tyrosine kinase inhibitor, Dabole® (Taletrectinib capsules). The data was released in both oral and poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting. A pooled analysis of long-term data from the TRUST-I and TRUST-II clinical trials showed that TKI-naïve patients achieved a median duration of response (mDOR) of nearly 50 months, a median progression-free survival (mPFS) of 46.1 months, and an objective response rate (ORR) of 89.8%. Dabole® is an oral, potent, centrally active, and highly selective next-generation ROS1 inhibitor. Taletrectinib has now received market approval in mainland China, Macau, the United States, Japan, and other regions, following priority review and breakthrough therapy designation by the NMPA and FDA.